Vnitr Lek 2020, 66(3):e22-e27 | DOI: 10.36290/vnl.2020.055

Cardiac involvement in hypereosinophilia

Lenka Roblová, Petr Kuchynka, Jan Kuchař, Tomáš Paleček
II. interní klinika - klinika kardiologie a angiologie 1. LF UK a VFN Praha

Cardiac abnormalities associated with hypereosinophilia represent rare diseases and occurs most commonly due to hypersensitivity or allergic reactions, other possible etiologies cover infections, malignancy, vasculitis or hypereosinophilic syndromes. Three stages of cardiac involvement are usually described. Initially, myocardial inflammation occurs, that can continue with a thrombotic stage and eventually progress to the last irreversible stage called endomyocardial fibrosis, which represents one of the acquired forms of restrictive cardiomyopathy. In most patients, increased levels of eosinophils in the blood differential test; however, it may not be present in the initial stages of the disease. Of the imaging methods, magnetic resonance imaging and positron emission tomography combined with CT PET-CT are used in addition to echocardiography. Endomyocardial biopsy may be indicated for definitive evidence of eosinophilic myocarditis. The clarification of the cause of hypereosinophilia is necessary for specific treatment of this disorder.

Keywords: endomyocardial fibrosis, eosinophilic myocarditis, hypereosinophilia, restrictive cardiomyopathy.

Published: May 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roblová L, Kuchynka P, Kuchař J, Paleček T. Cardiac involvement in hypereosinophilia. Vnitr Lek. 2020;66(3):e22-27. doi: 10.36290/vnl.2020.055.
Download citation

References

  1. Gotlib J. World Health Organization‑defined eosinophilic disorders: 2014 update on diagnosis, risk stratifacation and management. American Journal of Hematology 2014; 89: 325-337. Go to original source... Go to PubMed...
  2. Löffler W. Endokarditis parietalis fibroplastica mit bluteosinphilie. Ein eigenartiges Krankheitsbild. Schweiz Med Wochenschr 1936; 66: 817-820.
  3. Kuchynka P, Paleček T, Mašek M, et al. Current diagnostic and therapeutic aspects of eosinophilic myocarditis. Biomed Res Int 2016; Article ID 2829583. Go to original source...
  4. Al Ali AM, Straatman LP, Allard LF, et al. Eosinophillic myocarditis: case series and review of literature. Canadian Journal of Cardiology 2006; 22: 1233-1237. Go to original source... Go to PubMed...
  5. Marijon E Aspects of a neglected tropical cardiomyopathy: endomyocardial fibrosis. Arch Cardiovasc Dis 2008; 101: 801-802.
  6. Takkenberg JJM, Czer L, Fishbein M, et al. Eosinophilic myocarditis in patients awaiting heart transplantation. Critical Care Medicine 2004; 32: 714-721. Go to original source... Go to PubMed...
  7. Ball JK, Williams AW, Davies JN. Endomyocardial fibrosis. Lancet 1954; 266: 1049-1054. Go to original source... Go to PubMed...
  8. Yoshizawa S, Kato T, Mancini D, et al. Characteristics of patients with advanced heart failure having eosinophilic infiltration of the myocardium in the recent era: investigation of explanted hearts for transplantation. International Heart Journal 2013; 54: 146-148. Go to original source... Go to PubMed...
  9. Oakley C, Olsen E. Eosinophilia and heart disease. British Heart Journal 1977; 39: 233-237. Go to original source... Go to PubMed...
  10. Cugno M, Marzano A, Lorini M, et al. Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis. PLoS ONE 2014; 9: Article ID e111862. Go to original source...
  11. Seguea P, Iriart S, Acar P, et al. Eosinophilic cardiac disease: molecular, clinical and imaging aspects. Archives of Cardiovascular Diseases 2015; 108: 258-268. Go to original source... Go to PubMed...
  12. Akuthota P, Weller P. Spectrum of eosinophilic endorgan manifestations. Immunology and Allergy Clinics of North America 2015; 35: 403-411. Go to original source... Go to PubMed...
  13. Chusid MD, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27. Go to original source... Go to PubMed...
  14. Spear G. Eosinophilic explant carditis with eosinophilia: hypersensitivity to dobutamine infusion. Journal of Heart and LungTransplantation 1995; 14: 755-760.
  15. Ogbogu P, Bochner B, Butterfield J, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. Journal of Allergy and Clinical Immunology 2009; 124: 1319.e3-1325.e3. Go to original source... Go to PubMed...
  16. Brambatti M, Matassini MV, Adler E, et al. Eosinophilic myocarditis. JACC 2017; 70: 2363-2675. Go to original source... Go to PubMed...
  17. Caforio A, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal 2013; 34: 2636-2648. Go to original source... Go to PubMed...
  18. Kim N, Kim C, Kim J, et al. A hypereosinophilic syndrome with cardiac involvement from thrombotic stage to fibrotic stage, Journal of Cardiovascular Ultrasound 2015; 23: 100-102. Go to original source... Go to PubMed...
  19. Ommen S, Seward J, Tajik A. Clinical and echocardiographic features of hypereosinophilic syndromes. American Journal of Cardiology 2000; 86: 110-113. Go to original source... Go to PubMed...
  20. Dedieu N, Giardini A, Khambadkone A, et al. Eosinophilic heart disease in a paediatric patient. Eur J Echocardiogr 2011; 12: E3. Go to original source... Go to PubMed...
  21. Friedrich M, Sechtem U, Schulz‑Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. Journal of the American College of Cardiology 2009; 53: 1475-1487. Go to original source... Go to PubMed...
  22. Petersen S, Kardos A, Neubauer S. Subendocardialand papillary muscle involvement in a patient with Churg‑Strauss syndrome, detected by contrast enhanced cardiovascular magnetic resonance. Heart 2005; 91: article e9.
  23. James OG, Christensen JD, Wong TZ, et al. Utility of FDG PET.CT in inflammatory cardiovascular disease. Radiographics 2011; 31: 1271-1286. Go to original source... Go to PubMed...
  24. Greco A, Rizzo MI, De Virgilio A, et al. Churg‑Strauss syndrome, Autoimmunity Reviews 2015; 14: 341-348. Go to original source... Go to PubMed...
  25. Rezaizadeh H, Sanchez‑Ross M, Kaluski E, et al. Acute eosinophilic myokarditis: Diagnosis and treatment. Acute cardiac care 2010; 12: 31-36. Go to original source... Go to PubMed...
  26. Rothenberg M, Klion D, Roufosse F, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. The New England Journal of Medicine 2008; 358: 1215-1228. Go to original source... Go to PubMed...
  27. Lofiego C, Ferlito M, Rocchi G, et al. Ventricular remodeling in Loeffler endokarditis: implications for therapeutic decision making. Eur J Heart Fail 2005; 7: 1023-1026. Go to original source... Go to PubMed...
  28. Lepley Jr D, Aris A, Korns ME, et al. Endomyocardial fibrosis. A surgical approach. Ann Thorac Surg 1974; 18: 626-633. Go to original source... Go to PubMed...
  29. Metras D, Coulibaly AO, Quattara K. The surgical treatment of endomocardial fibrosis: results in 55 patients. Circulation 1985; 72: II274-II279.
  30. Tang A, Karski J, Butany J, et al. Severe mitral regurgitation in acute eosinophilic endomyocarditis: repair or replacement? Interact Cardiovasc Thorac Surg 2004; 3: 406-408. Go to original source... Go to PubMed...
  31. Legrand F, Klion A. Biologic therapies targeting eosinophils: current status and future prospects. The Journal of Allergy and Clinical Immunology: In Practice 2015; 3: 167-174. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.